NO20000045D0 - Farmasoeytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor - Google Patents

Farmasoeytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor

Info

Publication number
NO20000045D0
NO20000045D0 NO20000045A NO20000045A NO20000045D0 NO 20000045 D0 NO20000045 D0 NO 20000045D0 NO 20000045 A NO20000045 A NO 20000045A NO 20000045 A NO20000045 A NO 20000045A NO 20000045 D0 NO20000045 D0 NO 20000045D0
Authority
NO
Norway
Prior art keywords
inhibitor
pharmaceutical compositions
aldose reductase
ace
reductase inhibitor
Prior art date
Application number
NO20000045A
Other languages
English (en)
Other versions
NO20000045L (no
Inventor
Frank Carey
David Patrick Tuffin
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO20000045D0 publication Critical patent/NO20000045D0/no
Publication of NO20000045L publication Critical patent/NO20000045L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20000045A 1997-07-08 2000-01-06 Farmasøytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor NO20000045L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714274.9A GB9714274D0 (en) 1997-07-08 1997-07-08 Pharmaceutical composition
PCT/GB1998/001959 WO1999002189A1 (en) 1997-07-08 1998-07-02 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor

Publications (2)

Publication Number Publication Date
NO20000045D0 true NO20000045D0 (no) 2000-01-06
NO20000045L NO20000045L (no) 2000-01-06

Family

ID=10815469

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000045A NO20000045L (no) 1997-07-08 2000-01-06 Farmasøytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor

Country Status (28)

Country Link
US (1) US6337327B1 (no)
EP (1) EP0991424B1 (no)
JP (1) JP2002509540A (no)
KR (1) KR20010015551A (no)
CN (1) CN1186097C (no)
AT (1) ATE205402T1 (no)
AU (1) AU746211B2 (no)
BR (1) BR9810570A (no)
CA (1) CA2292451A1 (no)
CZ (1) CZ290276B6 (no)
DE (1) DE69801661T2 (no)
DK (1) DK0991424T3 (no)
ES (1) ES2163283T3 (no)
GB (1) GB9714274D0 (no)
HK (1) HK1028876A1 (no)
HU (1) HU224009B1 (no)
ID (1) ID24597A (no)
IL (1) IL133004A (no)
NO (1) NO20000045L (no)
NZ (1) NZ501165A (no)
PL (1) PL337925A1 (no)
PT (1) PT991424E (no)
RU (1) RU2216354C2 (no)
SK (1) SK122000A3 (no)
TR (1) TR199903026T2 (no)
UA (1) UA64761C2 (no)
WO (1) WO1999002189A1 (no)
ZA (1) ZA985993B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
AU2001238718A1 (en) 2000-03-02 2001-09-12 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
JP2005503378A (ja) * 2001-08-06 2005-02-03 ジエノメツド・エル・エル・シー Ａｃｅの過剰に関連する疾患の治療方法及び組成物
AU2002352145A1 (en) * 2001-11-26 2003-06-10 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20140243281A1 (en) 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20150197536A1 (en) * 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN103063794B (zh) * 2012-12-24 2014-08-06 扬子江药业集团南京海陵药业有限公司 一种依帕司他片的含量检测控制方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications

Also Published As

Publication number Publication date
WO1999002189A1 (en) 1999-01-21
PL337925A1 (en) 2000-09-11
DK0991424T3 (da) 2001-12-03
IL133004A (en) 2004-12-15
IL133004A0 (en) 2001-03-19
GB9714274D0 (en) 1997-09-10
PT991424E (pt) 2002-02-28
HK1028876A1 (en) 2001-03-09
EP0991424B1 (en) 2001-09-12
JP2002509540A (ja) 2002-03-26
DE69801661T2 (de) 2002-07-04
HUP0002644A2 (hu) 2000-12-28
CN1261804A (zh) 2000-08-02
RU2216354C2 (ru) 2003-11-20
AU8229698A (en) 1999-02-08
CA2292451A1 (en) 1999-01-21
DE69801661D1 (de) 2001-10-18
TR199903026T2 (xx) 2000-04-21
CN1186097C (zh) 2005-01-26
BR9810570A (pt) 2000-09-19
EP0991424A1 (en) 2000-04-12
CZ290276B6 (cs) 2002-06-12
US6337327B1 (en) 2002-01-08
UA64761C2 (uk) 2004-03-15
NO20000045L (no) 2000-01-06
CZ200017A3 (cs) 2000-05-17
ZA985993B (en) 1999-01-18
ATE205402T1 (de) 2001-09-15
SK122000A3 (en) 2000-06-12
ID24597A (id) 2000-07-27
NZ501165A (en) 2001-06-29
KR20010015551A (ko) 2001-02-26
ES2163283T3 (es) 2002-01-16
AU746211B2 (en) 2002-04-18
HU224009B1 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
NO20000045L (no) Farmasøytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor
NO20061736L (no) Krystallform av epotilon B
TR200001451T2 (tr) Aldoz redüktaz önleyici ve glikojen fosforilaz önleyici kombinasyonu.
IL151313A0 (en) Lipase containing pharmaceutical compositions
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
TR200103216T2 (tr) Pirimidinon bileşimleri
BR0107691A (pt) Sapogeninas substituìdas e seu uso
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
MXPA02002118A (es) Composiciones que contienen productos leguminosos.
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
MXPA02002119A (es) Productos leguminosos.
EP1178796A4 (en) AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
BR0111785A (pt) Composições e métodos para tratamento de candidìase
ATE418613T1 (de) Antimikrobielle zusammensetzungen
TR201900241T4 (tr) Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar.
DE60135454D1 (de) Pharmazeutische gel-zusammensetzung